Abstract:Background Pioglitazone is effective in nonalcoholic steatohepatitis (NASH), but the mechanisms of action are not completely understood. This study was designed to investigate the effects of pioglitazone on hepatic nuclear factor-kappa B (NF-kappa B) and cyclooxygenases-2 (COX-2) expression in NASH rats.Methods Thirty Sprague-Dawley male rats were randomly assigned to a control group (n=10), NASH group (n=10), and pioglitazone treatment group (n=10). Liver tissues were processed for histology by hematoxylin & eosin and Masson stained. Serum alanine aminotransferase (ALT), cholesterol, triglyceride, fasting blood glucose (FBG), fasting insulin (FINS) levels and biochemical parameters of antioxidant enzyme activities, tumor necrosis factor alpha (TNF-alpha), prostaglandin E-2 (PGE(2)) levels in serum and liver were measured. The mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPAR gamma), NF-kappa B and COX-2 were determined by real-time polymerase chain reaction, Western blotting and immunohistochemistry. One-way analysis of variance (ANOVA) and Wilcoxon's signed-rank test was used for the statistical analysis.Results There were severe steatosis, moderate inflammatory cellular infiltration and fibrosis in NASH rats. After pioglitazone treatment, steatosis, inflammation and fibrosis were significantly improved compared with the NASH group (chi(2)=20.40, P <0.001; chi(2)=20.17, P <0.001; chi(2)=13.98, P=0.002). Serum ALT, cholesterol, triglyceride, FBG, FINS levels were significantly elevated in the NASH group (P <0.05). In the NASH group, total anti-oxidation competence (T-AOC), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-PX) and malondialdehyde (MDA) levels in serum and liver were conspicuous disordered than those parameters in the control group. Meanwhile, TNF-alpha and PGE(2) levels in serum and liver were significantly increased compared with the control group. Immunohistochemistry showed NF-kappa B and COX-2 expression in liver was significantly elevated. However, PPAR gamma level was decreased in the NASH group. Real-time PCR and Western blotting revealed mRNA and protein expression of COX-2 were increased in the NASH group compared with the control group (0.57+/-0.08 vs. 2.83+/-0.24; 0.38+/-0.03 vs. 1.00+/-0.03, P <0.001 and P=0.004, respectively). After pioglitazone intervention, all of those parameters markedly improved (P <0.05 or P <0.01).Conclusion Down-regulating hepatic NF-kB and COX-2 expression, at least in part, is one of the possible therapeutic mechanisms of pioglitazone in NASH rats. Chin Med J 2012;125(13):2316-2321

Pioglitazone reduces lipid droplets in cholesterolosis of the gallbladder by increasing ABCA1 and NCEH1 expression

22(R)-hydroxycholesterol and pioglitazone synergistically decrease cholesterol ester via the PPARγ-LXRα-ABCA1 pathway in cholesterosis of the gallbladder.

Pioglitazone prevents cholesterol gallstone formation through the regulation of cholesterol homeostasis in guinea pigs with a lithogenic diet

Pioglitazone Ameliorates Nonalcoholic Steatohepatitis by Down-Regulating Hepatic Nuclear Factor-Kappa B and Cyclooxygenases-2 Expression in Rats.

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

Peroxisome Proliferator-Activated Receptor-γ Prevents Cholesterol Gallstone Formation in C57bl Mice by Regulating Bile Acid Synthesis and Enterohepatic Circulation

Pioglitazone enhanced the expression of genes involved in bile acid enterohepatic circulation in C57bl mice

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

Pioglitazone Reduces Tumor Necrosis Factor-Α Serum Concentration and Mrna Expression of Adipose Tissue in Hypercholesterolemic Rabbits

Pioglitazone, a PPAR-γ Activator, Attenuates the Severity of Cerulein-Induced Acute Pancreatitis by Modulating Early Growth Response-1 Transcription Factor

Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1.

Pioglitazone Can Improve Liver Sex Hormone-Binding Globulin Levels and Lipid Metabolism in Polycystic Ovary Syndrome by Regulating Hepatocyte Nuclear Factor-4Α

Glucagon-like peptide-1 contributes to increases ABCA1 expression by downregulating miR-758 to regulate cholesterol homeostasis.

The Protective Effects of Pioglitazone on Endothelial Function in Rats with Hypercholesterolemia

PPARγ Overexpression Regulates Cholesterol Metabolism in Human L02 Hepatocytes.

Effects of Pioglitazone on the Expression of Adipose Triglyceride Lipase in Obese Rats

Rosiglitazone Alleviates Intrahepatic Cholestasis Induced by Α‐naphthylisothiocyanate in Mice: the Role of Circulating 15‐deoxy‐δ12,14‐pgj2 and Nogo

Pioglitazone lowers serum retinol binding protein 4 by suppressing its expression in adipose tissue of obese rats.

Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.

Pioglitazone Modulates the Proliferation and Apoptosis of Vascular Smooth Muscle Cells Via Peroxisome Proliferators-Activated Receptor-Gamma

1945-P: Pioglitazone Promotes the Function of White and Brown Adipose Tissue in Diet-Induced Obese Mice